entertainment -WSS

entertainment

author：focus 2025-10-01 23:03:30 - browse：28

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Why workplace violence is so common in health care

focus

WSS

The UK government moves asylum

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Merck drug for rare lung condition set for approval in U.S.

Oprah kicked off a national conversation on obesity. Let's have it

The Readout: Lenmeldy, GLP

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Wikipedia

entertainment

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Supreme Court strikes down use of affirmative action

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

The high cost of giving birth even with insurance

Moderna hits safety problems in bold bid to reinvent medicine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Illinois to ban advertising for guns allegedly marketed to kids and militants

Peter Hotez and the public health issue of online harassment

The UK government moves asylum

hotspot

Readout Newsletter: Merck, Vertex, and Viking updates

There's no autism epidemic. It's an autism diagnosis epidemic

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Oprah kicked off a national conversation on obesity. Let's have it

Food as medicine: Medically tailored meals may get standardized

Primary care physicians play key roles in Alzheimer's management

focus

focus

knowledge

Wikipedia